524632 — Shukra Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapHigh Flyer

Annual income statement for Shukra Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	112	205	588	746	326
Cost of Revenue
Gross Profit	84.3	101	135	301	245
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	114	193	553	572	229
Operating Profit	-2.25	12.2	35.3	174	97.2
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	0.978	10.2	44.4	199	133
Provision for Income Taxes
Net Income After Taxes	1.88	7.51	44.1	185	95.8
Net Income Before Extraordinary Items
Net Income	1.88	7.51	44.1	185	95.8
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	1.88	7.51	44.1	185	95.8
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.105	0.025	0.655	0.423	0.219
Dividends per Share